The area of inherited condition testing for neurological conditions has become a major area of activity in the last decade or so, coinciding with the acceleration of sequencing and other technologies. Increasing awareness of neurological disorders, the aging population, and continued advancements in medical genetics will likely drive the neurological genetic testing market.
This report Genetic Testing Markets for Epilepsy, Autism, Alzheimer’s and Other Neurologic Conditions focuses on the neurological segments of the inherited/genetic disease testing market, including autism, Alzheimer’s disease and other neurological diseases. Next-generation sequencing has provided new abilities in recent years to affordably produce much larger volumes of sequence. It offers the choice of single genes, panels, exomes and other methods.
As part of its coverage, this report provides:
- Overview of Market
- Selected Companies and Products in the Neurological Genetic Testing Market
- Genetic Neurological Testing 2020-2025 (in $ millions)
- Genetic Testing by Disease Type (Autism, Alzheimer’s and other Neurological Diseases) 2020-2025 (in $ millions)
- COVID-19 Impact
- Companies in the Market
Table of Contents
CHAPTER 1: EXECUTIVE SUMMARY
OVERVIEW
SCOPE AND METHODOLOGY
MARKET OVERVIEW AND POTENTIAL
- Table 1-1: Genetic Neurological Testing 2020-2025 (in $ millions)
COVID-19 IMPACT
CHAPTER 2: INTRODUCTION
OVERVIEW
Autism
Alzheimer’s Disease
Other Neurological Diseases
Types of Testing
Limitations in Exome Sequencing
Costs of Exome Sequencing
Areas of Difficulty for NGS to Penetrate Market
Role of FISH/ISH
De Novo Mutations Not Excluded
CHAPTER 3: PRODUCTS AND MARKET POTENTIAL
GENETIC TESTING FOR AUTISM
GENETIC TESTING FOR ALZHEIMER’S DISEASE
GENETIC TESTING FOR OTHER SELECT NEUROLOGICAL DISEASES
- Table 3-1: Selected Companies and Products in the Neurological Genetic Testing Market
MARKET REVENUE AND FORECAST
- Table 3-2: Genetic Neurological Testing 2020-2025 (in $ millions)
- Table 3-3: Genetic Testing by Disease Type Autism, Alzheimer’s and other Neurological Diseases 2020-2025 (in $ millions)
CHAPTER 4: MARKET PARTICIPANTS
AMBRY GENETICS
- Table 4-1: Ambry Genetics Corporate Summary
- Company Information
ARUP LABORATORIES
- Table 4-2: ARUP Laboratories Corporate Details
- Company Information
ASURAGEN
- Table 4-3: Asuragen Corporate Summary
- Company Information
ATHENA DIAGNOSTICS, INC.
- Table 4-4: Athena Diagnostics Corporate Summary
- Company Information
BLUEPRINT GENETICS
- Table 4-5: Blueprint Genetics Corporate Summary
- Company Information
CENTOGENE AG
- Table 4-6: Centogene Corporate Summary
- Company Information
CYTOX GROUP LIMITED
- Table 4-7: Cytox Corporate Summary
- Company Information
FULGENT GENETICS
- Table 4-8: Fulgent Genetics Corporate Summary
- Company Information
GENEDX
- Table 4-9: GeneDx Corporate Summary
- Company Information
ILLUMINA
- Table 4-10: Illumina Corporate Summary
- Company Information
INVITAE
- Table 4-11: Invitae Corporate Summary
- Company Information
LABORATORY CORPORATION OF AMERICA
- Table 4-12: LabCorp Corporate Summary
- Company Information
LINEAGEN
- Table 4-13: Lineagen Corporate Summary
- Company Information
PERKINELMER, INC.
- Table 4-14: PerkinElmer Corporate Summary
- Company Information
QUEST
- Table 4-15: Quest Corporate Summary
- Company Information
THERMO FISHER SCIENTIFIC
- Table 4-16: Thermo Fisher Scientific Corporate Summary
- Company Information
Companies Mentioned
- Ambry Genetics
- Arup Laboratories
- Asuragen
- Athena Diagnostics
- Blueprint Genetics
- Centogene AG
- Cytox Group Limited
- Fulgent Genetics
- Genedx
- Illumina
- Invitae
- Laboratory Corporation of America
- Lineagen
- PerkinElmer
- Quest
- Thermo Fisher Scientific
